iBio, Inc.·4

Jan 30, 6:15 AM ET

Duran Felipe 4

4 · iBio, Inc. · Filed Jan 30, 2026

Research Summary

AI-generated summary of this filing

Updated

iBio (IBIO) CFO Felipe Duran Receives Option Award (179,000)

What Happened

  • Felipe Duran, Chief Financial Officer of iBio, received a derivative award reported as 179,000 shares on 2026-01-28. The filing lists the transaction value as $0.00 (derivative award). This was an award/grant (not a purchase or sale) and therefore does not represent a market buy or sell.

Key Details

  • Transaction date: 2026-01-28; Form 4 filed: 2026-01-30 (timely filing).
  • Transaction type: Grant / Award (derivative).
  • Amount: 179,000 shares reported; reported price $0.00.
  • Shares owned after transaction: Not specified in the provided filing summary.
  • Footnote on vesting: 25% vests on the one-year anniversary of the grant; remaining 75% vests in equal quarterly installments over the following 36 months (total ~4-year vesting schedule).
  • No indication of immediate sale or cashless exercise in the filing.

Context

  • This is a compensation-related option award (derivative) with a multi-year vesting schedule—commonly used for retention and incentive; it is not an open-market purchase that signals an immediate bullish bet.
  • Because this was an award (not a purchase or sale), it should be interpreted as routine executive compensation rather than a direct trading signal.

Insider Transaction Report

Form 4
Period: 2026-01-28
Duran Felipe
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    [F1]
    2026-01-28+179,000179,000 total
    Exercise: $2.23From: 2027-01-28Exp: 2036-01-27Common Stock (179,000 underlying)
Footnotes (1)
  • [F1]These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.
Signature
/s/ Felipe Duran|2026-01-30

Documents

1 file
  • 4
    tm264470-2_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT